Storia in 2 fonti

What's Going On With Viking Therapeutics Stock Wednesday? - Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics launches Phase 1 trial for obesity drug VK3019, a dual amylin/calcitonin receptor agonist. Read about the study.

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo2 mesi fa

Viking Therapeutics launches Phase 1 trial for obesity drug VK3019, a dual amylin/calcitonin receptor agonist. Read about the study.

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults